Bio-Techne in the news

Bio-Techne stock demonstrated market strength by outperforming industry peers during a recent trading day.

Bio-Techne Corp. stock outperformed its industry rivals during a strong day of market trading.

Bio-Techne and Refeyn launched a streamlined protein characterization workflow for bispecific antibodies to drive growth in high-margin instrumentation.

Bio-Techne is facing financial underperformance characterized by slow organic growth, a lack of scale in the life sciences sector, and diminishing returns on invested capital.

Trading strategies and market analysis perspectives for Bio-Techne Corporation's stock on the XETR exchange.

Bio-Techne and Refeyn have launched a combined workflow for characterization of bispecific antibodies and biosimilars using icIEF fractionation and mass photometry.

Financial metrics and database attribution for Bio-Techne Corporation's debt to equity ratio.

Bio-Techne's stock rose 4.5% post-earnings despite missing revenue and profit estimates due to significant operating margin expansion and cost reductions.

Bio-Techne Corp. stock outperformed its competitors during a strong day of market trading.

A new four-hour workflow integrates icIEF fractionation with mass photometry to correlate antibody charge variants with molecular size.

Bio-Techne and Refeyn have released a new integrated protein analysis workflow to speed up the characterization of complex bispecific antibodies.

Bio-Techne reported 3% organic growth and announced the sale of its Exosome Diagnostics business to focus on high-growth protein sciences and clinical tools.

Bio-Techne and Refeyn have launched a four-hour integrated workflow that combines icIEF fractionation and mass photometry to characterize charge and size variants in complex biotherapeutics.

Bio-Techne and Refeyn launched an integrated analytical workflow that combines protein charge separation and mass measurement to accelerate biologics development.

Bio-Techne is refocusing on high-margin proteomic tools and automated platforms while navigating a complex valuation landscape marked by recent share price volatility.

Bio-Techne and Refeyn launched a 4-hour workflow combining icIEF fractionation and mass photometry to accelerate the characterization of complex bispecific antibodies.

Bio-Techne stock rose on Wednesday but lagged behind the performance of its industry peers.

Financial analysis identifies a high risk-reward trading opportunity for Bio-Techne Corp based on positive momentum and mid-channel oscillation patterns.

Bio-Techne reported a 2% organic revenue decline due to weak biotech spending and order timing, despite strong performance in large pharma, spatial biology, and China.

A financial analysis of Bio-Techne highlights a potential 18% stock upside based on its strong position in the protein sciences and diagnostics markets.